Expanded Patents Highlight Treatment Potential for a Wide Array of Cancers

SILVER SPRING, Md.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB:NVLX), an emerging international biotechnology provider of cell and gene therapy solutions, including encapsulation of live cells and services through their associate SG Austria, released additional information today about the therapeutic potential surrounding the recently described patent ownership for its ability to treat a wide array of cancers and other diseases through antibody and antibody-like protein therapy.

Key parts of this family of patents are its ability to encapsulate and implant live cells proficient at producing unique proteins to treat specific diseases. Once implanted, the living cells will supply continuous quantities of critical therapeutic proteins, such as antibodies or antibody-like molecules.

Through extensive design and research, the ability to have continuous production will avoid typical peaks and troughs associated with standard injections, which make this such a powerful delivery method and can be used to treat an extremely wide variety of diseases. This includes diseases as diverse as Alzheimer’s, cancer, inflammatory diseases, pain management and others.

One critically useful aspect of encapsulation is its ability to be used for biotechnology and major pharmaceutical company’s antibody products already in use. This includes products in the multi-billion dollar cancer market such as: Avastin, Bexxar, CamPath, Erbitux, Herceptin, Mylotarg, Panorex, Rituxan and Zevalin through a single placement of encapsulated live antibody-expressing cells.

Dr. Robert F. Ryan, President and CEO, commented, “Through strategic planning, use of encapsulated cells producing existing treatment related proteins has and will continue to strengthen SG Austria and thereby Nuvilex. We believe this will ultimately allow Nuvilex to move many things ahead at full speed in the New Year. We plan to expand use of encapsulated cells for the clinical setting in the New Year and are already planning with companies to achieve this treatment potential. Lastly, Nuvilex and SG Austria wish everyone a happy, healthy and prosperous new year.”

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. Through our effort, all aspects of our corporate activities alone, and especially in concert with SG Austria, are rapidly moving toward completion. Our oncology offerings will include cancer treatments using the company’s industry-leading live-cell encapsulation technology. Current natural products also carried by Nuvilex include BiaDiagnostics certified Gluten-Free Cinnergen™, 3 oz. travel size Cinnergen™, Cinnechol™ and others to enhance a healthy lifestyle, cosmetic use, flu treatment, tattoo inks, antimicrobial and antinematodal agents.

Safe Harbor Statement

This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.



CONTACT:

Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.